Compile Data Set for Download or QSAR
Report error Found 123 Enz. Inhib. hit(s) with all data for entry = 12035
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674206(N-({(1r,4r)-4-[6- (1-tert-butyl-1H- pyrazol-4-yl)-...)
Affinity DataIC50: 2.60nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674198(2,3,5-trifluoro-4-hydroxy-N- ({(1r,4r)-4-[6- (pyri...)
Affinity DataIC50: 2.70nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674205(N-({(1r,4r)-4-[6-(3-cyclopropyl- 1-methyl-1H- pyra...)
Affinity DataIC50: 2.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674210(3,5-difluoro-4- hydroxy-N- {[(1r,4r)-4-{6-[1- (pro...)
Affinity DataIC50: 3.20nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674211(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(1- meth...)
Affinity DataIC50: 3.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674279(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(1,3- th...)
Affinity DataIC50: 3.70nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674218(N-({(1r,4r)-4-[6- (5,6-dihydro- 4H-pyrrolo[1,2-b] ...)
Affinity DataIC50: 3.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674232(3,5-difluoro-4- hydroxy-N-({(1r,4r)-4- [6-(1-methy...)
Affinity DataIC50: 3.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674196(N-{[(1r,4r)-4-(6- chloro-2H- indazol-2- yl)cylohex...)
Affinity DataIC50: 4.30nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674202(N-({(1r,4r)-4-[5- (cyclopropyl-methoxy)-2H- pyrazo...)
Affinity DataIC50: 4.30nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674209(N-({(1r,4r)-4-[6- (1,5-dimethyl- 1H-pyrazol-4-yl)-...)
Affinity DataIC50: 4.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674215(3,5-difluoro-4- hydroxy-N- {[(1r,4r)-4-{6-[1- (oxe...)
Affinity DataIC50: 4.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674200(2,3,5-trifluoro-4-hydroxy-N- ({(1r,4r)-4-[6-(1- me...)
Affinity DataIC50: 4.60nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674223(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(4- meth...)
Affinity DataIC50: 4.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674266(3,5-difluoro-4- hydroxy-N-({(1r,4r)- [6-(1,3-thiaz...)
Affinity DataIC50: 4.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674207(N-({(1r,4r)-4- [6-(2,3- dihydropyrazolo[5,1- b][1,...)
Affinity DataIC50: 5.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674177(2,3,5-trifluoro-4-hydroxy-N- [(4-{3-[5-(trifluorom...)
Affinity DataIC50: 5.5nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674278(3,5-difluoro-4- hydroxy-N-({(1r,4r)- 4-[6-(2-metho...)
Affinity DataIC50: 5.5nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674226(N-({(1r,4r)-4- [6-(2-cyanophenyl)- 2H-indazol-2-yl...)
Affinity DataIC50: 5.60nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674264(3,5-difluoro-4- hydroxy-N-({(1r,4r)- 4-[6-(2-methy...)
Affinity DataIC50: 5.60nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674201(2,3,5-trifluoro-4-hydroxy-N- ({(1r,4r)-4-[7-(1- me...)
Affinity DataIC50: 5.70nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674222(N-({(1r,4r)-4- [6-(4,6- dimethylpyrimidin-2- yl)-2...)
Affinity DataIC50: 5.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674213(N-({(1r,4r)-4-[6- (1-cyclopropyl- 1H-pyrazol-4-yl)...)
Affinity DataIC50: 6.5nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674289(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(5- meth...)
Affinity DataIC50: 6.5nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674184(N-{[(1r,4r)-4- {6-[1-(2,2- difluoroethyl)-1H- pyra...)
Affinity DataIC50: 7.10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674242(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6- (pyridi...)
Affinity DataIC50: 7.10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674228(3,5-difluoro-4- hydroxy-N-{[(1r,4r)-4- {6-[5-(hydr...)
Affinity DataIC50: 7.5nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674230(3,5-difluoro-4- hydroxy-N-({(1r,4r)- 4-[6-(1-methy...)
Affinity DataIC50: 7.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674234(3,5-difluoro-4- hydroxy-N-({(1r,4r)- 4-[6-(3- meth...)
Affinity DataIC50: 7.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674272(3,5-difluoro-4- hydroxy-N-({(1r,4r)- 4-[6-(imidazo...)
Affinity DataIC50: 7.90nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674267(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(7H- pyr...)
Affinity DataIC50: 8.20nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674199(2,3,5-trifluoro-4-hydroxy-N- ({(1r,4r)-4-[6- (pyra...)
Affinity DataIC50: 8.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674231(3,5-difluoro-4- hydroxy-N-({(1r,4r)- 4-[6-(pyridin...)
Affinity DataIC50: 8.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674283(3,5-difluoro-4- hydroxy-N-{[(1r,4r)- 4-{6-[2-(morp...)
Affinity DataIC50: 8.60nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674194(3,5-difluoro-4- hydroxy-N- {[(1r,4r)-4-(6-methoxy-...)
Affinity DataIC50: 8.70nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674224(N-({(1r,4r)-4-[6-(5- cyclopropylpyrimidin- 2-yl)-2...)
Affinity DataIC50: 8.70nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674259(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6- (pyrazo...)
Affinity DataIC50: 8.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674290(3,5-difluoro-4- hydroxy-N-{[(1r,4r)- 4-(4-methoxy-...)
Affinity DataIC50: 8.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674208(3,5-difluoro-4- hydroxy-N- {[(1r,4r)-4-{6-[1- (oxo...)
Affinity DataIC50: 9.5nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674216(3,5-difluoro-4- hydroxy-N- {[(1r,4r)-4-{6-[1- meth...)
Affinity DataIC50: 9.5nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674233(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(6- meth...)
Affinity DataIC50: 9.60nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674284(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(5- meth...)
Affinity DataIC50: 9.70nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674197(N-{[(1r,4r)-4-(5-chloro-2H- indazol-2-yl) cyclohex...)
Affinity DataIC50: 10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674241(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6- (pyrida...)
Affinity DataIC50: 10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674260(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(5- meth...)
Affinity DataIC50: 10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674268(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(1,2- th...)
Affinity DataIC50: 10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674277(3,5-difluoro-4- hydroxy-N-({(1r,4r)- 4-[6-(6-metho...)
Affinity DataIC50: 10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674281(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(1H- pyr...)
Affinity DataIC50: 10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674291(3,5-difluoro-4- hydroxy-N-({4-[3-(6- methylpyridaz...)
Affinity DataIC50: 10nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Pfizer

US Patent
LigandPNGBDBM674182(3,5-difluoro-4-hydroxy- N-({(1r,4r)-4-[6-(2- metho...)
Affinity DataIC50: 11nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 123 total ) | Next | Last >>
Jump to: